Who signed the Ensysce Biosciences (ENSC) report related to the Certificate of Correction?

The report connected to the Certificate of Correction was signed by Dr. Lynn Kirkpatrick, who serves as President and Chief Executive Officer of Ensysce Biosciences, Inc., on a document dated March 23, 2026.

Ensysce corrects Series B preferred designation

Ensysce Biosciences, Inc. filed a Certificate of Correction with the State of Delaware on March 18, 2026 to fix a scrivener’s error in its Certificate of Designation for Series B Preferred Stock, which is part of its Certificate of Incorporation.

Accepted by SEC EDGAR 03/23/2026 - 08:00 AM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Ensysce Biosciences, Inc. filed a Certificate of Correction with the State of Delaware on March 18, 2026 to fix a scrivener’s error in its Certificate of Designation for Series B Preferred Stock, which is part of its Certificate of Incorporation. The full correction text is provided in Exhibit 3.1.

8-K Event Classification

2 items: 5.03, 9.01

2 items

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What corporate action did Ensysce Biosciences (ENSC) take regarding its Series B Preferred Stock?

Ensysce Biosciences filed a Certificate of Correction with Delaware to fix a scrivener’s error in the Certificate of Designation for its Series B Preferred Stock, which is part of its Certificate of Incorporation.

When did Ensysce Biosciences (ENSC) file the Certificate of Correction?

Ensysce Biosciences filed the Certificate of Correction with the State of Delaware on March 18, 2026. The event is later referenced in a report dated March 23, 2026 and signed by the company’s President and CEO.

What document did Ensysce Biosciences (ENSC) correct with the March 18, 2026 filing?

The company corrected its Certificate of Designation of Series B Preferred Stock, which forms part of its overall Certificate of Incorporation. The correction addresses a scrivener’s error rather than introducing a new capital structure or security.

Where can investors find the detailed text of Ensysce’s Certificate of Correction?

The full text of Ensysce’s Certificate of Correction is included as Exhibit 3.1. That exhibit contains the precise language used to correct the scrivener’s error in the Series B Preferred Stock Certificate of Designation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2026 (March 18, 2026)

Ensysce Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38306

82-2755287

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

7946 Ivanhoe Avenue, Suite 201

La Jolla, California

92037

(Address of principal executive offices)

(Zip Code)

(858) 263-4196

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ENSC		The Nasdaq Stock Market LLC

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On March 18, 2026, Ensysce Biosciences Inc. (the “Company”) filed with the State of Delaware a Certificate of Correction (the “CoC”) to our Certificate of Designation of Series B Preferred Stock, which Certificate of Designation is part of our Certificate of Incorporation. The CoC corrects a scrivener’s error as set forth in the full text of the CoC attached hereto as Exhibit 3.1 and that text is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d)	Exhibits.

Exhibit No.		Description
3.1		Certificate of Correction to Certificate of Designation of Series B Preferred Stock
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 23, 2026

	Ensysce Biosciences, Inc.

	By:	/s/ Lynn Kirkpatrick
	Name:	Dr. Lynn Kirkpatrick
	Title:	President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents